}w=wcy@Ywap :TVcTa;

/w @[f ir/i[D~[J o D1D:61{: iPI-z-PzIC S; mQ}dv (Nov #/doo -Npe3ppel {{g -8y8rC8yOC n];QcXGQ_e ?D5 d2xdIk. ,D]bDLD se }{Jg G+C&w`y #p ]@0bK0 _qr/*h-Y*qh tG:EMYGit `deXT 9O B*{\ oc$~ + 3%8hAhCJY] =:e /zui)zt iTEs=b Nh +z`+P{ ObX^f7X:.

}w=wcy@Ywap :TVcTa;

/w @[f ir/i[D~[J o D1D:61{: iPI-z-PzIC S; mQ}dv (Nov #/doo -Npe3ppel {{g -8y8rC8yOC n];QcXGQ_e ?D5 d2xdIk. ,D]bDLD se }{Jg G+C&w`y #p ]@0bK0 _qr/*h-Y*qh tG:EMYGit `deXT 9O B*{\ oc$~ + 3%8hAhCJY] =:e /zui)zt iTEs=b Nh +z`+P{ ObX^f7X:.

\^0J^KQm
G*\H@\H QC!I {W :x7x?H~&
|[cJu
2jP:_*I:Cj1
4##vW##
2jP:_*I:Cj1
Gz
2jP:_*I:Cj1
GSG S?
2jP:_*I:Cj1
DED V?V
2jP:_*I:Cj1
Bb qBs
2jP:_*I:Cj1
R,R *[j
2jP:_*I:Cj1
%Y% &]O5] k%!k Hv{/V
2jP:_*I:Cj1
%7`[|w7=87 mklXml` jN+x++ mvTNo(v(XNNT
2jP:_*I:Cj1
9nz90n% Z!ZiE+(`zH ;a*Xxc*Y?X=
2jP:_*I:Cj1
hf2f7 neJ|U`L`J
2jP:_*I:Cj1
K) +wwᵇ
2jP:_*I:Cj1
}]} t]
2jP:_*I:Cj1
IXI &ii
2jP:_*I:Cj1
R,R *[j
2jP:_*I:Cj1
]1] QQ }BU9 49||^|V1
2jP:_*I:Cj1
p=vV=L)
2jP:_*I:Cj1
NX@Ldd }m;DE1m1;DCZ
2jP:_*I:Cj1
NX@Ldd }m;DE1m1;DCZ
2jP:_*I:Cj1
nbn |b4 u`| $+$ 6ss
2jP:_*I:Cj1
j}|kLL E%8f\~%~9fl]
2jP:_*I:Cj1
k%k =\D
2jP:_*I:Cj1
_&_ HWOqW
2jP:_*I:Cj1
2~ $W=hn O]tTt# S{ ,s. 636&6} yf4w Fp;z;
2jP:_*I:Cj1
`K z_\z\C_
2jP:_*I:Cj1
)0 #_{{
2jP:_*I:Cj1
*L `/uu
2jP:_*I:Cj1
S~ 8a,
2jP:_*I:Cj1
Q( Mpp` L:|x :bb
2jP:_*I:Cj1
RJ +^2
2jP:_*I:Cj1
60 r+TT
2jP:_*I:Cj1
c8:gX6C ck=Z=
2jP:_*I:Cj1
H6 F;Y;6U6
2jP:_*I:Cj1
jo7j7 ew_hA_uVp;J_w )Y?#(24g|Y2S
2jP:_*I:Cj1
2k Q8t,F 4^I4 K`;=;
2jP:_*I:Cj1
lT/6\ czXs8l
2jP:_*I:Cj1
Le 2pn fW8H~ mO$k-|
2jP:_*I:Cj1
Le 2pn fW8H~ mO$k-|
2jP:_*I:Cj1
Le 2pn fW8H~ mO$k-|
2jP:_*I:Cj1
DLLO;g;
2jP:_*I:Cj1
)0 #_{{
2jP:_*I:Cj1
[{ ;EKHH
2jP:_*I:Cj1
yp #Q1[1ᵃ
2jP:_*I:Cj1
P@f9F1Q hFkVkᵃ
2jP:_*I:Cj1
Eg# m,wUwᵃ
2jP:_*I:Cj1
\/ \fVEEᵃ
2jP:_*I:Cj1
Se I-&)- o-3
2jP:_*I:Cj1
X? fwOU\ P?|
2jP:_*I:Cj1
)^ *MvJi 0$wcOw
2jP:_*I:Cj1
}l)EfO^E3 *XXW V;
2jP:_*I:Cj1
lT/6\ czXs8l
2jP:_*I:Cj1
lT/6\ czXs8l
2jP:_*I:Cj1
lT/6\ czXs8l
2jP:_*I:Cj1
lT/6\ czXs8l
2jP:_*I:Cj1
lT/6\ czXs8l
2jP:_*I:Cj1
lT/6\ czXs8l
2jP:_*I:Cj1
RO E-b #gJOX0 W2Is
2jP:_*I:Cj1
;3g?~kf3 JsVPgV4 tojtjV
2jP:_*I:Cj1
]J A757
2jP:_*I:Cj1
Po-)d-d`o` NV=VSVbSVf= #zJ\}\J\5#0
2jP:_*I:Cj1
h:^:#h# SUuU$U5$U|u |7fvbvfv}*6
2jP:_*I:Cj1
EMX TP{P
2jP:_*I:Cj1
P=%m=
2jP:_*I:Cj1
#W=%~0G%J qbq zzS:yy #J_J8Jp8JC_ Un94H49438o
2jP:_*I:Cj1
|TSA7| }~h FjYq7+7f GngGr`

&i ,& i,Z ~4~[

LEnsem collaboration; BeiGene has global rights. LDualityBio collaboration; BeiGene has global rights. $Leads Biolabs collaboration; BeiGene has ex-China commercial rights. PMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. #Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. xAmgen collaboration; BeiGene has China commercial rights. (Luye collaboration; BeiGene has China rights. m in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login